Compare BIRK & ASND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BIRK | ASND |
|---|---|---|
| Founded | 1774 | 2006 |
| Country | United Kingdom | Denmark |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 12.8B |
| IPO Year | 2023 | 2015 |
| Metric | BIRK | ASND |
|---|---|---|
| Price | $42.67 | $209.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 15 |
| Target Price | $64.69 | ★ $256.40 |
| AVG Volume (30 Days) | ★ 2.9M | 700.0K |
| Earning Date | 02-19-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 83.10 | N/A |
| EPS | ★ 2.19 | N/A |
| Revenue | ★ $2,460,904,611.00 | $758,592,045.00 |
| Revenue This Year | $14.52 | $98.90 |
| Revenue Next Year | $14.40 | $83.74 |
| P/E Ratio | $19.06 | ★ N/A |
| Revenue Growth | 16.22 | ★ 97.46 |
| 52 Week Low | $38.16 | $118.03 |
| 52 Week High | $62.66 | $229.94 |
| Indicator | BIRK | ASND |
|---|---|---|
| Relative Strength Index (RSI) | 50.67 | 51.33 |
| Support Level | $40.59 | $207.28 |
| Resistance Level | $43.02 | $215.98 |
| Average True Range (ATR) | 1.80 | 7.30 |
| MACD | -0.22 | 0.31 |
| Stochastic Oscillator | 33.62 | 67.56 |
Birkenstock Holding PLC is a company that manufactures and sells footbed-based products, including sandals, closed-toe silhouettes, and other products, such as skincare and accessories, for everyday, leisure, and work. It sells its products through two main channels: business-to-business (B2B) which comprises sales made to established third-party store networks, and direct-to-consumer (DTC) which comprises sales made on globally owned online stores through the Birkenstock.com domain and sales made in Birkenstock retail stores. The company's reportable segments are based on its regional hubs and include: the Americas which is also its key revenue-generating segment; Europe; and Australia, Japan, India, China, and the United Arab Emirates (APMA).
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.